Different studies have also shown the usefulness of DPP-4 inhibitors (linagliptin) both in preventing T2D in patients with prediabetes20, and in reducing insulin requirements and improving metabolic control in patients with in-hospital hyperglycemia after kidney transplantation when combined with insulin16, and they are mainly indicated for uncontrolled patients with T2D who do not meet glucose control21,22. Here, DPP4 is linked to Hyperglycemia.